NASDAQ:AVTX Avalo Therapeutics - AVTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.85 -0.16 (-7.96%) (As of 03/23/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.81▼$2.0850-Day Range$1.85▼$5.0052-Week Range$1.81▼$11.28Volume48,985 shsAverage Volume18,114 shsMarket Capitalization$17.41 millionP/E RatioN/ADividend YieldN/APrice Target$15.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Avalo Therapeutics MarketRank™ ForecastAnalyst RatingReduce1.00 Rating ScoreUpside/Downside737.8% Upside$15.50 Price TargetShort InterestHealthy0.36% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.75Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.04) to ($2.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.81 out of 5 starsMedical Sector766th out of 989 stocksPharmaceutical Preparations Industry368th out of 480 stocks 2.5 Analyst's Opinion Consensus RatingAvalo Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.50, Avalo Therapeutics has a forecasted upside of 737.8% from its current price of $1.85.Amount of Analyst CoverageAvalo Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.36% of the float of Avalo Therapeutics has been sold short.Short Interest Ratio / Days to CoverAvalo Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avalo Therapeutics has recently increased by 30.53%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvalo Therapeutics does not currently pay a dividend.Dividend GrowthAvalo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVTX. Previous Next 1.3 News and Social Media Coverage News SentimentAvalo Therapeutics has a news sentiment score of -0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Avalo Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 9 people have searched for AVTX on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat Follows3 people have added Avalo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avalo Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders45.40% of the stock of Avalo Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.46% of the stock of Avalo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Avalo Therapeutics are expected to decrease in the coming year, from ($1.04) to ($2.57) per share.Price to Book Value per Share RatioAvalo Therapeutics has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Avalo Therapeutics (NASDAQ:AVTX) StockAvalo Therapeutics, Inc. is a biopharmaceutical company. engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.Read More Receive AVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AVTX Stock News HeadlinesMarch 23, 2023 | finance.yahoo.comRoche (RHHBY) & Lilly to Co-Develop Alzheimer's Detection DeviceMarch 7, 2023 | finance.yahoo.comAvalo to Present at Oppenheimer's 33rd Annual Healthcare ConferenceMarch 24, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.February 2, 2023 | finance.yahoo.comAvalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and WarrantsFebruary 2, 2023 | msn.comAvalo Therapeutics stock slides 20% after hours on stock and warrants offeringFebruary 2, 2023 | finance.yahoo.comAvalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and WarrantsJanuary 17, 2023 | finance.yahoo.comAvalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic AsthmaNovember 30, 2022 | msn.comLooking Into Avalo Therapeutics's Return On Capital EmployedMarch 24, 2023 | Weiss Ratings (Ad)Banking NightmareDuring and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …November 29, 2022 | seekingalpha.comAVTX Avalo Therapeutics, Inc.November 7, 2022 | finanznachrichten.deAvalo Therapeutics: Avalo Reports Third Quarter 2022 Financial Results and Provides Business UpdatesNovember 7, 2022 | msn.comRecap: Avalo Therapeutics Q3 EarningsNovember 7, 2022 | benzinga.comAvalo Reports Third Quarter 2022 Financial Results and Provides Business UpdatesNovember 7, 2022 | finance.yahoo.comAvalo Sells Economic Rights to Previously Out-Licensed Assets for $5 MillionNovember 7, 2022 | finance.yahoo.comAvalo Reports Third Quarter 2022 Financial Results and Provides Business UpdatesSeptember 9, 2022 | finance.yahoo.comAre Options Traders Betting on a Big Move in Avalo Therapeutics (AVTX) Stock?September 7, 2022 | finance.yahoo.comWall Street Analysts Predict a 191% Upside in Avalo Therapeutics, Inc. (AVTX): Here's What You Should KnowSeptember 6, 2022 | finance.yahoo.comAvalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling StageSeptember 1, 2022 | finance.yahoo.comAvalo to Present at the H.C. Wainwright Global Investment ConferenceAugust 25, 2022 | msn.comAvalo Therapeutics Earnings Perspective: Return On Capital EmployedAugust 11, 2022 | finance.yahoo.comAvalo Therapeutics Announces Board ChangesAugust 10, 2022 | finance.yahoo.comWall Street Analysts Predict a 230% Upside in Avalo Therapeutics, Inc. (AVTX): Here's What You Should KnowAugust 4, 2022 | finance.yahoo.comAvalo Reports Second Quarter 2022 Financial Results and Provides Business UpdatesAugust 4, 2022 | finance.yahoo.comAvalo Reports Second Quarter 2022 Financial Results and Provides Business UpdatesAugust 2, 2022 | seekingalpha.comAvalo to get ~15M upfront in license deal with Apollo Therapeutics for AVTX-007August 2, 2022 | finance.yahoo.comAvalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)August 1, 2022 | finance.yahoo.comAvalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo TherapeuticsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AVTX Company Calendar Last Earnings3/02/2022Today3/23/2023Next Earnings (Estimated)3/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVTX CUSIPN/A CIK1534120 Webwww.avalotx.com Phone(410) 522-8707FaxN/AEmployees42Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.50 High Stock Price Forecast$21.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+737.8%Consensus RatingReduce Rating Score (0-4)1.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-84,380,000.00 Net Margins-293.77% Pretax Margin-293.37% Return on Equity-950.78% Return on Assets-96.69% Debt Debt-to-Equity RatioN/A Current Ratio1.07 Quick Ratio1.07 Sales & Book Value Annual Sales$5.40 million Price / Sales3.22 Cash FlowN/A Price / Cash FlowN/A Book Value$2.47 per share Price / Book0.75Miscellaneous Outstanding Shares9,410,000Free Float5,140,000Market Cap$17.41 million OptionableOptionable Beta1.66 Key ExecutivesGarry Arthur NeilChairman, President & Chief Executive OfficerChristopher SullivanChief Financial OfficerLisa HeggVice President-Research & Development ProgramsColleen MatkowskiVice President-Global Regulatory AffairsKey CompetitorsLannettNYSE:LCIAkari TherapeuticsNASDAQ:AKTXGeoVax LabsNASDAQ:GOVXShuttle PharmaceuticalsNASDAQ:SHPHMolecular TemplatesNASDAQ:MTEMView All CompetitorsInsiders & InstitutionsNantahala Capital Management LLCSold 7,147 shares on 2/15/2023Ownership: 5.746%Millennium Management LLCSold 7,819 shares on 2/15/2023Ownership: 0.459%Susquehanna International Group LLPBought 18,671 shares on 2/14/2023Ownership: 0.198%Garry Arthur NeilBought 2,083 shares on 12/9/2022Total: $9,206.86 ($4.42/share)View All Insider TransactionsView All Institutional Transactions AVTX Stock - Frequently Asked Questions Should I buy or sell Avalo Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avalo Therapeutics in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" AVTX shares. View AVTX analyst ratings or view top-rated stocks. What is Avalo Therapeutics' stock price forecast for 2023? 1 brokers have issued 1 year target prices for Avalo Therapeutics' shares. Their AVTX share price forecasts range from $10.00 to $21.00. On average, they predict the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 737.8% from the stock's current price. View analysts price targets for AVTX or view top-rated stocks among Wall Street analysts. How have AVTX shares performed in 2023? Avalo Therapeutics' stock was trading at $5.0401 on January 1st, 2023. Since then, AVTX stock has decreased by 63.3% and is now trading at $1.85. View the best growth stocks for 2023 here. Are investors shorting Avalo Therapeutics? Avalo Therapeutics saw a increase in short interest in February. As of February 28th, there was short interest totaling 24,800 shares, an increase of 30.5% from the February 13th total of 19,000 shares. Based on an average daily volume of 15,400 shares, the short-interest ratio is currently 1.6 days. Currently, 0.4% of the shares of the company are sold short. View Avalo Therapeutics' Short Interest. When is Avalo Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023. View our AVTX earnings forecast. How were Avalo Therapeutics' earnings last quarter? Avalo Therapeutics, Inc. (NASDAQ:AVTX) announced its earnings results on Wednesday, March, 2nd. The company reported ($1.92) earnings per share for the quarter, missing the consensus estimate of ($1.80) by $0.12. Avalo Therapeutics had a negative net margin of 293.77% and a negative trailing twelve-month return on equity of 950.78%. When did Avalo Therapeutics' stock split? Avalo Therapeutics's stock reverse split on Friday, July 8th 2022. The 1-12 reverse split was announced on Friday, July 8th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 8th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is Avalo Therapeutics' stock symbol? Avalo Therapeutics trades on the NASDAQ under the ticker symbol "AVTX." Who are Avalo Therapeutics' major shareholders? Avalo Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (5.75%), Millennium Management LLC (0.46%), Susquehanna International Group LLP (0.20%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Armistice Capital, Llc, Christopher Ryan Sullivan, Garry Arthur Neil, H Jeffrey Wilkins and Schond L Greenway. View institutional ownership trends. How do I buy shares of Avalo Therapeutics? Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Avalo Therapeutics' stock price today? One share of AVTX stock can currently be purchased for approximately $1.85. How much money does Avalo Therapeutics make? Avalo Therapeutics (NASDAQ:AVTX) has a market capitalization of $17.41 million and generates $5.40 million in revenue each year. How can I contact Avalo Therapeutics? Avalo Therapeutics' mailing address is 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713. The official website for the company is www.avalotx.com. The company can be reached via phone at (410) 522-8707 or via email at ir@cerecor.com. This page (NASDAQ:AVTX) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.